A fed­er­al judge has sus­pend­ed the Pen­tagon's des­ig­na­tion of WuXi AppTec as a com­pa­ny with al­leged ties to the Chi­nese mil­i­tary.

Judge James Boas­berg wrote...

Mass­a­chu­setts biotech Schol­ar Rock said it's pulling an em­bat­tled In­di­ana-based man­u­fac­tur­ing site from its ap­pli­ca­tion for a po­ten­tial new spinal mus­cu­lar at­ro­phy drug, af­ter the...

The FDA re­ject­ed ITM Iso­tope Tech­nolo­gies Mu­nich’s ra­dio­phar­ma­ceu­ti­cal agent for neu­roen­docrine tu­mors be­cause of man­u­fac­tur­ing is­sues, de­lay­ing a po­ten­tial chal­lenger to No­var­tis’ ap­proved drug Lu­tathera...

Bris­tol My­ers Squibb re­vealed plansfor a $2.3 bil­lion man­u­fac­tur­ing cam­pus in Hous­ton, part of the com­pa­ny's pledge last year to in­vest $40 bil­lion in...

Jazz Phar­ma­ceu­ti­cals will buyAc­tio Bio­sciences for $820 mil­lion up­front and up to $500 mil­lion more if cer­tain mile­stones are met for its ul­tra-rare epilep­sy...

Sion­na Ther­a­peu­tics’ bid to be­come the next cys­tic fi­bro­sis drug de­vel­op­er af­ter Ver­tex Phar­ma­ceu­ti­cals has tak­en a ma­jor hit, af­ter Sion­na re­port­edthat its lead...